Is Jacobs Stock a Buy as Strong Growth Meets Execution & Debt Risks?

Jacobs’ Backlog Supports the Growth Case

Jacobs ended the fiscal third quarter of 2026 with a backlog of $28.9 billion, up 27.3% year over year. The quarterly gross revenue book-to-bill ratio was 1.5, while the trailing 12-month ratio held at 1.4.

Net revenues and gross profit embedded in backlog rose 11% and 14%, respectively. Management believes the current backlog can support fiscal 2027 growth at least in line with the company’s long-term average, giving Jacobs better revenue visibility than its recent reported growth alone suggests.

J’s End Markets Offer Multiple Growth Paths

Infrastructure & Advanced Facilities adjusted net revenues increased 9.9% organically to $2.09 billion. Life Sciences and Advanced Manufacturing led the advance with 24.2% growth, driven by data-center and semiconductor activity, while Critical Infrastructure increased 9.4% on transportation and energy and power demand.

The broader engineering market shows similar spending support. AECOM ACM reported record backlog and raised fiscal 2026 earnings guidance after its second quarter, while Fluor Corporation FLR cited new awards across power, data centers, mining and other markets in its first-quarter update. Those peers reinforce that infrastructure demand is broad, though project selection and execution remain important differentiators.

Jacobs’ Profitability Is Moving Higher

Adjusted EBITDA increased 16.7% year over year to $366.8 million, and the margin expanded 109 basis points to 15.2%. Adjusted operating profit rose 10.8%, showing that organic growth and operating leverage are translating into better profitability.

Management raised fiscal 2026 guidance for the third consecutive quarter. Jacobs now expects adjusted earnings of $7.20-$7.30 per share, adjusted net revenue growth of 9.5-10% and an adjusted EBITDA margin of 14.7-14.8%.

J’s Debt and Cash Adjustments Require Caution

Long-term debt reached $3.58 billion at June 26, 2026, compared with $2.24 billion at fiscal 2025-end, largely reflecting the acquisition of the remaining PA Consulting interest. Net leverage nevertheless declined to 1.8 from 2.1 in the prior quarter, reaching the company’s below-2.0 target early.

Reported operating cash flow was $456.1 million, while adjusted free cash flow totaled $541 million after excluding $110 million of employee-related payments tied to the transaction. The gap between reported and adjusted conversion means investors should continue tracking cash generation as Jacobs balances deleveraging, dividends and repurchases.

Jacobs’ Valuation Reflects Some Improvement

Jacobs trades at 17.9X forward 12-month earnings, below 18.4X for its Zacks sub-industry, 20.7X for the Zacks Construction sector and 20.9X for the S&P 500. That relative discount leaves room for continued operating improvement to support the shares.

The stock still trades above its five-year median of 16.9X. Investors are therefore already paying something for the stronger backlog, margin trajectory and earnings outlook, reducing the cushion if project delays, cost overruns or public-funding shifts weaken results.

J’s Ratings Favor Patience With Selective Optimism

The bottom line is that Jacobs has a credible growth case, but the stock is not an uncomplicated buy. Record backlog, expanding margins and diversified demand support selective optimism, while leverage, adjusted cash-flow items and large-project execution argue for entry-price discipline.

Jacobs currently carries a Zacks Rank #2 (Buy), and the Zacks Consensus Estimate for current-year earnings has moved 0.5% higher in the past four weeks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Its Momentum Score of B supports the near-term price trend, but the Value Score of C, Growth Score of D and VGM Score of D show a less consistent profile across investment styles. That mix favors patience rather than an aggressive all-in decision.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research